SCHEMBL5000846

SCHEMBL5000846

Fc1cccc(-c2cncc(N3CCN(c4ccc(F)cc4F)CC3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
PIM2 Q9P1W9 13/20 0.44
RAD52 P43351 1/20 0.44
PIM1 P11309 3/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2A1 P68400 1/20 0.41
DHFR P00374 1/20 0.41
PIM3 Q86V86 2/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994571 0.90 SMN1; SMN2 (0.51) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL4997591 0.87 CYP11B1 (0.47) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL4997581 0.87 PIM2 (0.48) PIM2PIM1CSNK2A2CSNK2A1LMNA
SCHEMBL5003421 0.85 MEN1 (0.50) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL5003086 0.85 CYP11B1 (0.47) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL20460140 0.84 CYP11B1 (0.60) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL4991829 0.84 CYP11B1 (0.46) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL5003458 0.84 PHGDH (0.46) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL4991836 0.82 PIM2 (0.48) CYP11B1CYP11B2PIM2RAD52PIM1
SCHEMBL4997778 0.82 PIM1 (0.49) CYP11B1CYP11B2PIM2PIM1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C CYP11B1 132/4885CYP11B2 112/4885PIM2 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.